Project 1: Fibrolamellar HCC

NIH RePORTER · NIH · P50 · $425,451 · view on reporter.nih.gov ↗

Abstract

PROJECT 1 – PROJECT SUMMARY Fibrolamellar hepatocellular carcinoma (FLHCC) is an often-lethal disease affecting primarily children and young adults. The poor prognosis is exacerbated by the lack of both existing diagnostic tests and systemic therapy. We have recently demonstrated that there is a single, consistent deletion in one copy of chromosome 19 in FLHCC patients that results in a chimeric gene. This chimera encodes a fusion protein, a constitutively active catalytic subunit of protein kinase A. This project has two aims: (1) develop the first diagnostic tests for this cancer and (2) develop the first blockers for the driver for this cancer.

Key facts

NIH application ID
10468829
Project number
5P50CA210964-05
Recipient
MAYO CLINIC ROCHESTER
Principal Investigator
MICHAEL S TORBENSON
Activity code
P50
Funding institute
NIH
Fiscal year
2022
Award amount
$425,451
Award type
5
Project period
2018-09-10 → 2024-08-31